These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36375679)

  • 1. Censoring Time Trade-off Values at 0 Versus at -1: How Does the Assumption for Worse-Than-Dead Time Trade-off Values Affect the Modeling of EQ-5D-5L Valuation Data?
    Yang Z; Rand K; Luo N
    Value Health; 2023 May; 26(5):685-693. PubMed ID: 36375679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
    Gandhi M; Rand K; Luo N
    Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Censoring in the time trade-off valuation of worse-than-dead EQ-5D-5L health states: can a time-based willingness-to-accept question be the solution?
    Liao M; Rand K; Yang Z; Hsu CN; Lin HW; Luo N
    Qual Life Res; 2023 Apr; 32(4):1165-1174. PubMed ID: 36564637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication.
    Chang JA; Hsu CN; Ramos-Goñi JM; Luo N; Lin HW; Lin FJ
    Eur J Health Econ; 2024 Aug; 25(6):1041-1055. PubMed ID: 38072877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
    Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach.
    Ramos-Goñi JM; Craig BM; Oppe M; Ramallo-Fariña Y; Pinto-Prades JL; Luo N; Rivero-Arias O
    Value Health; 2018 May; 21(5):596-604. PubMed ID: 29753358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
    Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
    Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
    Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
    Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
    Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
    Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
    Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match?
    Augestad LA; Rand K; Luo N; Barra M
    Value Health; 2020 Apr; 23(4):487-494. PubMed ID: 32327166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New methods for modelling EQ-5D-5L value sets: An application to English data.
    Feng Y; Devlin NJ; Shah KK; Mulhern B; van Hout B
    Health Econ; 2018 Jan; 27(1):23-38. PubMed ID: 28833854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states.
    Yang Z; Rand K; Stolk E; Busschbach J; Luo N
    Eur J Health Econ; 2024 Sep; 25(7):1087-1094. PubMed ID: 38104294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling ranking, time trade-off, and visual analog scale values for EQ-5D health states: a review and comparison of methods.
    Craig BM; Busschbach JJ; Salomon JA
    Med Care; 2009 Jun; 47(6):634-41. PubMed ID: 19433996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
    Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
    Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.